Triomics, a San Francisco-based start-up, recently announced that it has raised $15 million in new funding to further develop its artificial intelligence (AI) platform aimed at matching cancer patients with clinical trials and emerging treatments. According to Triomics CEO Sarim Khan, the workload involved in manually reviewing patients’ charts can lead to clinical delays and patients missing out on potentially life-saving treatments. The company’s platform, which utilizes large language models, aims to automate this process and increase accuracy in matching patients to trials.
Currently, around 20% of patient data is easily accessible, while the remaining 80% is unstructured data that requires manual searching by oncologists. Triomics’ AI-driven solution claims to be able to match patients to trials with 95% accuracy in just a matter of minutes, significantly reducing the time and effort required by healthcare providers to identify suitable treatment options. Khan emphasizes that the primary goal of the platform is to maximize patient access to the best possible care by streamlining the process of identifying and enrolling in clinical trials.
In addition to improving patient access to trials and treatments, Triomics’ technology has other applications such as automating manual processes in healthcare settings. The company markets the platform as a tool that can assist healthcare providers in a variety of use cases, from quality assurance to tracking clinical pathways. Anai Kothari, a surgical oncologist at the Medical College of Wisconsin Cancer Center, praises the platform’s ability to convert complex cancer data into actionable insights that can enhance patient care.
Triomics’ success since its launch in 2020 can be attributed to its strategic focus on bringing together expertise in AI research and clinical oncology. The company’s CTO and co-founder, Hrituraj Singh, highlights the deliberate recruitment of specialists in both areas, resulting in a team with a deep understanding of customizing language models for oncology-specific applications. As a result, Triomics has established partnerships with multiple hospital and healthcare providers and is actively working towards commercializing its platform.
The company’s recent funding round, which attracted investors such as Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, is aimed at supporting Triomics’ continued growth and expansion. Dev Khare, a partner at Lightspeed, acknowledges the potential of Triomics’ platform to automate clinical trials and streamline cancer center workflows using existing healthcare datasets and generative AI. Jishnu Bhattacharjee, managing director at Nexus Venture Partners, believes that Triomics is well-positioned to deliver significant value to cancer care providers and patients, not only in the US but globally.
With plans to onboard more hospital and healthcare partners, Triomics aims to reach up to 15 institutions by the end of the year. The company’s focus on leveraging AI technology to improve patient outcomes and streamline clinical processes has garnered significant attention from the healthcare industry and investors alike. Through its innovative platform, Triomics is poised to revolutionize the way cancer specialists identify and match patients with personalized treatment options, ultimately leading to better outcomes for individuals battling cancer.
